An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
CONCLUSIONS: In this Phase I study, DMUC4064A demonstrated a tolerable safety profile along with encouraging efficacy in the indication of platinum-resistant OC.PMID:34627611 | DOI:10.1016/j.ygyno.2021.09.023
Source: Gynecologic Oncology - Category: Cancer & Oncology Authors: Joyce Liu Howard Burris Judy S Wang Lisa Barroilhet Martin Gutierrez Yulei Wang Anjali Vaze Renee Commerford Stephanie Royer-Joo Voleak Choeurng Eric Humke Kathleen Moore Source Type: research
More News: Anemia | Cancer | Cancer & Oncology | Constipation | Epithelial Cancer | Ovarian Cancer | Ovaries | Pain | Study | Toxicology